Boehringer Says Retailers' Aggrenox Suits Still Must Be Nixed
Boehringer Ingelheim Pharmaceuticals Inc. and other drugmakers continued their push to dismiss six retailers' pay-for-delay lawsuits over the stroke drug Aggrenox, arguing a recent ruling in a similar case does nothing...To view the full article, register now.
Already a subscriber? Click here to view full article